skip to content »

Pulmonary

Houston, Texas

The Alkek Building at Baylor College of Medicine
Section of Pulmonary, Critical Care, and Sleep Medicine
not shown on screen

Adaani E. Frost, M.D.

Adaani Frost, M.D.Professor of Medicine

Baylor College of Medicine
One Baylor Plaza - BCM621
Houston, Texas 77030
Phone: 713-798-2400
Fax: 713-798-2688
E-mail: frost@bcm.edu

Education

  • M.D., Memorial University of Newfoundland, St. John's, Newfoundland, Canada
  • Residency, Internal Medicine, Toronto General Hospital, Toronto, Ontario, Canada
  • Residency, Internal Medicine, University Hospital, University of Alberta, Edmonton, Alberta, Canada
  • Fellowship, Pulmonary Medicine, Toronto General Hospital, Toronto, Ontario, Canada
  • Clinical Pulmonary Transplant Research Fellowship, Toronto Lung Transplant Group, University of Toronto, Ontario, Canada
  • Fellowship, Pulmonary Medicine, McGill University Hospital System, Montreal, Canada

Clinical and Research Interests

Dr. Frost's clinical and research interests include pulmonary hypertension, end stage lung disease, RV failure, and pulmonary fibrosis.

Awards and Honors

  • Best Doctors in America® 2009-2010 - Houston Metro Area
  • Frueauff Foundation Award, Frueauff Foundation, 2001-2005

Selected Publications

  • Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon M. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest. 2009.
  • Benza RL, Barst RJ, Galie N, Frost A, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming TR, Naeije R. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest. 2008; 134(4):775-82. Erratum in: Chest. 2009; 135(4):1114.
  • Keogh AM, Mayer E, Benza RL, Corris P, Dartevelle PG, Frost AE, Kim NH, Lang IM, Pepke-Zaba J, Sandoval J.Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S67-77.
  • McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009; 135(1):122-9.
  • Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Harrison BC, Despain D, Dufton C, Rubin LJ; ARIES Study Group. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(21):1971-81.
  • Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-30. Erratum in: Ann Intern Med. 2009;150(1):63. Ann Intern Med. 2009;151(6):435.
  • Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, Oudiz RJ, Robbins IM, Seibold JR, Shapiro S, Tapson VF, Barst RJ. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis. 2007; 66(11):1467-72.
  • Kaza V, Katz MF, Cumming S, Frost AE, Safdar Z. Correlation of chest radiograph pattern with genotype, age, and gender in adult cystic fibrosis: a single-center study. Chest. 2007; 132(2):569-74.
  • McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, et al. Randomized study of adding inhaled Iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006.
  • Walker AM, Langleben D, Lorelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst RJ, Bourge RC, Channick R, Frost A, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006, 152(3): 521-526.

E-mail this page to a friend